Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCF1 | P14598 | 1/20 | 0.42 |
| ▸ | PLG | P00747 | 1/20 | 0.39 |
| ▸ | PLAT | P00750 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10216772 | 1.00 | NCF1 (0.42) | NCF1PLGPLATLMNA | |
| SCHEMBL8275064 | 1.00 | NCF1 (0.42) | NCF1PLGPLATLMNA | |
| Acetic Acid SCHEMBL5046443 | 0.87 | LMNA (0.50) | NCF1PLGPLATLMNA | |
| SCHEMBL12014105 | 0.85 | NCF1 (0.34) | NCF1PLGPLATLMNA | |
| SCHEMBL1421597 | 0.82 | NCF1 (0.41) | NCF1PLGPLATLMNA | |
| SCHEMBL3153434 | 0.80 | NCF1 (0.48) | NCF1PLGPLATLMNA | |
| SCHEMBL6476697 | 0.80 | LMNA (0.41) | NCF1PLGPLATLMNA | |
| SCHEMBL7404625 | 0.80 | LMNA (0.41) | NCF1PLGPLATLMNA | |
| SCHEMBL7397429 | 0.80 | LMNA (0.41) | NCF1PLGPLATLMNA | |
| SCHEMBL6476699 | 0.80 | LMNA (0.41) | NCF1PLGPLATLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023154291-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-08-17 | — | — | WO | disclosed |
| US-20230255240-A1 | OLIGOSACCHARIDE COMPOSITIONS FOR USE AS ANIMAL FEED AND METHODS OF PRODUCING THEREOF | MIDORI USA, INC. | 2023-08-17 | — | — | US | disclosed |
| US-11691989-B2 | Macrocyclic indoles as Mcl-1 inhibitors | ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) | 2023-07-04 | — | — | US | disclosed |
| EP-4198030-A1 | IMMUNOREGULATORY COMPOUND AND ANTITUMOR APPLICATION THEREOF | Shanghaitech University (CN) | 2023-06-21 | — | — | EP | disclosed |
| US-11653676-B2 | Oligosaccharide compositions for use as animal feed and methods of producing thereof | DSM NUTRITIONAL PRODUCTS, LLC (US) | 2023-05-23 | — | — | US | disclosed |
| US-20230138480-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-05-04 | — | — | US | disclosed |
| US-20230132715-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-05-04 | — | — | US | disclosed |
| US-20230138480-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-05-04 | — | — | US | disclosed |
| US-20230065740-A1 | CYCLIN-DEPENDENT KINASE INHIBITORS | SPV THERAPEUTICS INC. | 2023-03-02 | — | — | US | disclosed |
| US-20230058729-A1 | MACROCYCLES AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2023-02-23 | — | — | US | disclosed |
| US-20090163373-A1 | Method of Drug Design | ALCHEMIA LIMITED (AU) | 2009-06-25 | — | — | US | disclosed |
| US-20070004729-A1 | Methods and compositions of novel triazine compounds | REDDY US THERAPEUTICS, INC. | 2007-01-04 | — | — | US | disclosed |
| US-20050171128-A1 | Pyrrolo[2,3-d]pyrimidine compounds | PFIZER INC | 2005-08-04 | — | — | US | disclosed |
| US-6890929-B2 | Immunosuppressants; lupus, multiple sclerosis, skin disorders, antiarthritic agents, antihistamines, antiulcer agents, Crohn's disease | PFIZER, INC. (US) | 2005-05-10 | — | — | US | disclosed |
| EP-1087970-B1 | PYRROLO 2,3-d]PYRIMIDINE COMPOUNDS | PFIZER PROD INC (US) | 2004-04-28 | — | — | EP | disclosed |
| US-20030212273-A1 | Pyrrolo [2,3-D] pyrimidine compounds | PFIZER INC. | 2003-11-13 | — | — | US | disclosed |
| US-6610847-B2 | Tyrosine kinase inhibitors; immunosuppressants | PFIZER INC. | 2003-08-26 | — | — | US | disclosed |
| US-20020019526-A1 | Pyrrolo[2,3-d]pyrimidine compounds | PFIZER INC. | 2002-02-14 | — | — | US | disclosed |
| EP-1087970-A1 | PYRROLO 2,3-d]PYRIMIDINE COMPOUNDS | Pfizer Products Inc. (US) | 2001-04-04 | — | — | EP | disclosed |
| WO-1999065908-A1 | PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS | PFIZER PRODUCTS INC. (US) | 1999-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230132715-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | NCF1 2891/4885PLG 1441/4885PLAT 1236/4885 |
| US-20230255240-A1 | OLIGOSACCHARIDE COMPOSITIONS FOR USE AS ANIMAL FEED AND METHODS OF PRODUCING THEREOF | FUT5, FUT6, OSTC | NCF1 2402/4885PLG 1886/4885PLAT 3149/4885 |
| US-20070004729-A1 | Methods and compositions of novel triazine compounds | AREG, TGFB1, PTGIS | NCF1 2930/4885PLG 14/4885PLAT 51/4885 |
| US-20230138480-A1 | COMPOUNDS AND USES THEREOF | VHL, CLN6, TFEB | NCF1 2708/4885PLG 2731/4885PLAT 3761/4885 |
| US-20020019526-A1 | Pyrrolo[2,3-d]pyrimidine compounds | JAK1, JAK3, JAK2 | NCF1 1894/4885PLG 2668/4885PLAT 1436/4885 |
| US-11653676-B2 | Oligosaccharide compositions for use as animal feed and methods of producing thereof | FUT5, FUT6, OSTC | NCF1 2402/4885PLG 1886/4885PLAT 3149/4885 |
| US-20230065740-A1 | CYCLIN-DEPENDENT KINASE INHIBITORS | CDK2, CDK1, CCNK | NCF1 1308/4885PLG 2938/4885PLAT 2329/4885 |
| US-20050171128-A1 | Pyrrolo[2,3-d]pyrimidine compounds | JAK3, JAK1, JAK2 | NCF1 2256/4885PLG 2534/4885PLAT 1286/4885 |
| US-11691989-B2 | Macrocyclic indoles as Mcl-1 inhibitors | MCL1, BCL2A1, BCL2L1 | NCF1 2369/4885PLG 4718/4885PLAT 4801/4885 |
| US-20230058729-A1 | MACROCYCLES AS FACTOR XIA INHIBITORS | TFPI, TFPI2, F11 | NCF1 1027/4885PLG 62/4885PLAT 23/4885 |
| US-20030212273-A1 | Pyrrolo [2,3-D] pyrimidine compounds | JAK1, JAK3, JAK2 | NCF1 1894/4885PLG 2668/4885PLAT 1436/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.